And then of course was there's the recent $30 billion purchase of Actelion, a leading pulmonary hypertension drug maker. Johnson & Johnson paid for this deal with its overseas cash reserves, and management expects the deal to ultimately result in long-term top and bottom lines sales growth acceleration of 1% and 1.5% to 2%, respectively.